# language_name_wals:	English
# language_name_glotto:	English
# ISO_6393:	eng
# year_composed:	NA
# year_published:	NA
# mode:	written
# genre_broad:	technical
# genre_narrow:	NA
# writing_system:	Latn
# special_characters:	NA
# short_description:	EMEA
# source:	https://object.pouta.csc.fi/OPUS-EMEA/v3/raw/en.zip
# copyright_short:	http://opus.nlpl.eu/EMEA.php
# copyright_long:	http://opus.nlpl.eu/EMEA.php J. Tiedemann, 2012, Parallel Data, Tools and Interfaces in OPUS. In Proceedings of the 8th International Conference on Language Resources and Evaluation (LREC 2012)
# sample_type:	whole
# comments:	NA

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1/ 22 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabigen SAG2 oral suspension, for red foxes and raccoon dogs.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance:
Live attenuated rabies virus, SAG2 strain
minimum 8 log10 CCID50*/ dose
* CCID50:
Cell Culture Infective Dose 50%
Excipients:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension
4.
CLINICAL PARTICULARS
4.1 Target species
Red foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides).
4.2 Indications for use, specifying the target species
For the active immunisation of red foxes and raccoon dogs to prevent infection by rabies virus.
The duration of protection is of at least 6 months.
4.3 Contraindications
None.
4.4 Special warnings for each target species
Not applicable.
4.5 Special precautions for use
Special precautions for use in animals
Baits shall not be distributed in inhabited areas, roads and watery areas.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
It is recommended to wear rubber gloves.
People handling and distributing this vaccine should be vaccinated against rabies.
Immunocompromised/ immunosuppressed individuals must not be allowed to handle this vaccine.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet or the label to the physician.
2/ 22 4.6 Adverse reactions (frequency and seriousness)
No undesirable effects have been shown for Rabigen SAG2.
As this vaccine presentation contains traces of gentamicin and contains tetracycline as biomarker, occasional hypersensitivity reactions may be observed in domestic animals that have accidentally ingested the bait.
4.7 Use during pregnancy, lactation or lay
The safety of the vaccine in pregnant and lactating animals has not been investigated.
However rabies virus and attenuated rabies vaccine viruses do not usually accumulate in reproductive organs and are not known to directly affect reproductive functions.
4.8 Interaction with other medicinal products and other forms of interaction
None known.
4.9 Amounts to be administered and administration route
The baits are distributed by land or by air within the framework of vaccination campaigns against rabies.
They are intended to be eaten by foxes / raccoon dogs.
The intake of a single bait is sufficient to ensure active immunisation to prevent infection by rabies virus.
The distribution rate depends on the topography and on the population of the target species.
The minimum distribution rate is:
- 13 baits per square km over the areas where fox / raccoon dog density indexes were equal or less
than 3 foxes / raccoon dogs seen per 10 km.
- 20 baits per square km over the areas where fox / raccoon dog density indexes were more than 3
foxes / raccoon dogs seen per 10 km.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
The administration of the vaccine at 10 times the recommended dosage induced no undesirable effects.
4.11 Withdrawal period
Not applicable.
5.
IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group:
Live viral vaccines ATCvet code:
QI07BD.
Rabigen SAG2 is a live modified rabies vaccine for oral administration to red foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides).
The active ingredient is a double low virulence mutant isolated from the SAD Bern strain of rabies virus by two successive selection steps in order to avoid natural reversion to the parental strain.
It is used for the active immunisation of foxes and raccoon dogs characterised by the induction of rabies specific antibodies.
3/ 22 6.
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Vaccine:
Disodium phosphate - Potassium dihydrogen phosphate - Glutamic acid – Saccharose – Gelatin – Tryptone - Lactalbumin hydrolysate - Sodium chloride - Water for injection
Appetent matrix (bait):
Rhodor 7046R antifoam - Tetracycline (Hcl) HD - EVA (Ethyl Vinyl Acetate) - White soft paraffin - Paraffin 50/ 52° C - Seah Saur - Natural fish aroma
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
2 years at -20°C and 2 days at +25°C.
6.4 Special precautions for storage
Store in a freezer at -40°C to -20°C.
Protect from light.
Keep the boxes tightly closed.
6.5 Nature and composition of immediate packaging
Liquid vaccine contained within an aluminium/ PVC sachet coated with an appetising matrix.
The baits are successively packed in boxes of:
- 200 units (4x50)
- 400 units (2x200)
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Dispose of waste material and any unplaced baits at the end of the day of distribution by boiling or incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
7.
MARKETING AUTHORISATION HOLDER
VIRBAC S. A.
1ère Avenue 2065m L. I. D.
06516 Carros - France tel: + 33 4 92 08 73 04 fax: + 33 4 92 08 73 48 e-mail: dar@virbac. fr
8.
MARKETING AUTHORISATION NUMBERS
EU/ 2/ 00/ 021/ 001 EU/ 2/ 00/ 021/ 002
4/ 22 9.
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
06/ 04/ 2000 / 11/ 04/ 2005
10 DATE OF REVISION OF THE TEXT
16/ 04/ 2008
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
PROHIBITION OF SALE, SUPPLY AND/ OR USE
The import, sale, supply and/ or use of this veterinary medicinal product is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Any person intending to import, sell, supply and/ or use the veterinary medicinal product must consult the relevant Member State’ s Competent Authority on the current vaccination policies prior to the import, sale, supply and/ or use.
Restricted to duly designated competent administrative authorities.
5/ 22 ANNEX II
A.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
D.
STATEMENT OF THE MRLs
6/ 22 A.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer of the biological active substance
VIRBAC SA L. I. D.
1ère Avenue - 2065 m 06516 Carros, France
Manufacturing Authorisation issued on December 22nd 1997 by the Ministère de la solidarité, de la santé et de la protection sociale – Direction de la Pharmacie et du médicament – République Française.
Name and address of the manufacturer responsible for batch release
VIRBAC SA L. I. D.
1ère Avenue - 2065 m 06516 Carros, France
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
Veterinary medicinal product subject to prescription.
The import, sale, supply and/ or use of this veterinary medicinal product is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Any person intending to import, sell, supply and/ or use the veterinary medicinal product must consult the relevant Member State’ s Competent Authority on the current vaccination policies prior to the import, sale, supply and/ or use.
Restricted to duly designated competent administrative authorities.
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
Not applicable.
D.
STATEMENT OF THE MRLs
Not applicable.
7/ 22 ANNEX III
LABELLING AND PACKAGE LEAFLET
8/ 22 A.
LABELLING
9/ 22 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
200 unit box
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabigen SAG2 oral suspension, for red foxes and raccoon dogs.
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Active substance:
Live attenuated rabies virus, SAG2 strain
8 log10 - CCID50*/ dose
* CCID50:
Cell Culture Infective Dose 50%
Excipients:
Palatable matrix (bait) containing a tetracycline biomarker
3.
PHARMACEUTICAL FORM
Oral suspension.
4.
PACKAGE SIZE
200 (4 x 50) vaccinal baits.
5.
TARGET SPECIES
Red foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides).
6.
INDICATION
For the active immunisation of red foxes and raccoon dogs to prevent infection by rabies virus.
The duration of protection is of at least 6 months.
7.
METHOD AND ROUTE OF ADMINISTRATION
The baits are distributed by land or by air within the framework of vaccination campaigns against rabies.
They are intended to be eaten by foxes and raccoon dogs.
The intake of a single bait is sufficient to ensure active immunisation to prevent infection by rabies virus.
The distribution rate depends on the topography and on the population of the target species.
This minimum distribution rate is:
- 13 baits per square km over the areas where fox / raccoon dog density indexes were equal or
less than 3 foxes / raccoon dogs seen per 10 km.
- 20 baits per square km over the areas where fox / raccoon dog density indexes were more than 3
foxes / raccoon dogs seen per 10 km.
10/ 22 Read the package leaflet before use.
8.
SPECIAL WARNINGS, IF NECESSARY
It is recommended to wear rubber gloves.
People handling and distributing this vaccine should be vaccinated against rabies.
Immunocompromised/ immunosuppressed individuals must not be allowed to handle this vaccine.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet i or the label to the physician.
As this vaccine presentation contains traces of gentamicin and contains tetracycline as biomarker, occasional hypersensitivity reactions may be observed in domestic animals that have accidentally ingested the bait.
9.
EXPIRY DATE
EXP:
{month/ year}
10.
SPECIAL STORAGE CONDITIONS
Store in a freezer at -40°C to -20°C.
Protect from light.
Keep the boxes tightly closed.
11.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Dispose of waste material and any unplaced baits at the end of the day of distribution by boiling or incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
12.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
Restricted to duly designated competent administrative authorities.
The import, sale, supply and/ or use of this veterinary medicinal product is or may be prohibited in certain Member States on the whole or part of their territory, see package insert for further information.
13.
THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
11/ 22 14.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
VIRBAC S. A.
1ère Avenue 2065m L. I. D.
06516 Carros - France
15.
MARKETING AUTHORISATION NUMBER
EU/ 2/ 00/ 021/ 001
16.
MANUFACTURER’ S BATCH NUMBER
BN:
{number}
12/ 22 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
400 unit box
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabigen SAG2 oral suspension, for red foxes and raccoon dogs.
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Active substance:
Live attenuated rabies virus, SAG2 strain
8 log10 - CCID50*/ dose
* CCID50:
Cell Culture Infective Dose 50%
Excipients:
Palatable matrix (bait) containing a tetracycline biomarker
3.
PHARMACEUTICAL FORM
Oral suspension.
4.
PACKAGE SIZE
400 (2 x 200) vaccinal baits
5.
TARGET SPECIES
Red foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides).
6.
INDICATION
For the active immunisation of red foxes and raccoon dogs to prevent infection by rabies virus.
The duration of protection is of at least 6 months.
7.
METHOD AND ROUTE OF ADMINISTRATION
The baits are distributed by land or by air within the framework of vaccination campaigns against rabies.
They are intended to be eaten by foxes / raccoon dogs.
The intake of a single bait is sufficient to ensure active immunisation to prevent infection by rabies virus.
The distribution rate depends on the topography and on the population of the target species.
This minimum distribution rate is:
- 13 baits per square km over the areas where fox / raccoon dog density indexes were equal or
less than 3 foxes / raccoon dogs seen per 10 km.
- 20 baits per square km over the areas where fox / raccoon dog density indexes were more than 3
foxes / raccoon dogs seen per 10 km.
13/ 22 Read the package leaflet before use.
8.
SPECIAL WARNINGS, IF NECESSARY
It is recommended to wear rubber gloves.
People handling and distributing this vaccine should be vaccinated against rabies.
Immunocompromised/ immunosuppressed individuals must not be allowed to handle this vaccine.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet or the label to the physician.
As this vaccine presentation contains traces of gentamicin and contains tetracycline as biomarker, occasional hypersensitivity reactions may be observed in domestic animals that have accidentally ingested the bait.
9.
EXPIRY DATE
EXP:
{month/ year}
10.
SPECIAL STORAGE CONDITIONS
Store in a freezer at -40°C to -20°C.
Protect from light.
Keep the boxes tightly closed.
11.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Dispose of waste material and any unplaced baits at the end of the day of distribution by boiling or incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
12.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
Restricted to duly designated competent administrative authorities.
The import, sale, supply and/ or use of this veterinary medicinal product is or may be prohibited in certain Member States on the whole or part of their territory, see package insert for further information.
13.
THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
14/ 22 14.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
VIRBAC S. A.
1ère Avenue 2065m L. I. D.
06516 Carros - France
15.
MARKETING AUTHORISATION NUMBER
EU/ 2/ 00/ 021/ 002
16.
MANUFACTURER’ S BATCH NUMBER
BN:
{number}
15/ 22 MINIMUM PARTICULARS TO APPEAR ON SACHETS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabigen SAG2 oral suspension, for red foxes and raccoon dogs.
2.
BATCH NUMBER
BN:
{number}
3.
EXPIRY DATE
EXP:
{month/ year}
4.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
RABIES VACCINE DO NOT TOUCH
Informative phone number: + 33 4 92 08 73 04
16/ 22 PARTICULARS TO APPEAR ON BAITS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabigen SAG2 oral suspension, for red foxes and raccoon dogs.
2.
NAME OF THE MARKETING AUTHORISATION HOLDER
VIRBAC S. A.
1ère Avenue 2065 M L. I. D 06516 Carros France
3.
EXPIRY DATE
EXP:
{month/ year}
4.
BATCH NUMBER
BN:
{number}
5.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
RABIES VACCINE DO NOT TOUCH
Informative phone number: + 33 4 92 08 73 04
17/ 22 B.
PACKAGE LEAFLET
18/ 22 PACKAGE LEAFLET Rabigen SAG2 oral suspension, for red foxes and raccoon dogs.
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
VIRBAC S. A.
1ère Avenue 2065m L. I. D.
06516 Carros France
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabigen SAG2 oral suspension, for red foxes and raccoon dogs.
3.
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
Active substance:
Live attenuated rabies virus, SAG2 strain
8 log10 CCID50*/ dose
* CCID50:
Cell Culture Infective Dose 50%
Excipients:
Palatable matrix (bait) containing a tetracycline biomarker
4.
INDICATION
For the active immunisation of red foxes and raccoon dogs to prevent infection by rabies virus.
The duration of protection is of at least 6 months.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
No undesirable effects have been shown for Rabigen SAG2.
As this vaccine presentation contains traces of gentamicin and contains tetracycline as biomarker, occasional hypersensitivity reactions may be observed in domestic animals that have accidentally ingested the bait.
7.
TARGET SPECIES
Red foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides).
19/ 22 8.
DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION
The intake of a single bait is sufficient to ensure active immunisation to prevent infection by rabies virus.
The baits are distributed by land or by air within the framework of vaccination campaigns against rabies.
They are intended to be eaten by foxes / raccoon dogs.
The distribution rate depends on the topography and on the population of the target species.
This minimum distribution rate is:
- 13 baits per square km over the areas where fox / raccoon dog density indexes were equal or
less than 3 foxes / raccoon dogs seen per 10 km.
- 20 baits per square km over the areas where fox / raccoon dog density indexes were more than 3
foxes / raccoon dogs seen per 10 km.
9.
ADVICE ON CORRECT ADMINISTRATION
Baits shall not be distributed in inhabited areas, roads and watery areas.
10.
WITHDRAWAL PERIOD
Not applicable.
11.
SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children Store in a freezer at -40°C to -20°C.
Protect from light.
Keep the boxes tightly closed.
12.
SPECIAL WARNINGS
For animal treatment only.
It is recommended to wear rubber gloves.
People handling and distributing this vaccine should be vaccinated against rabies.
The safety of the vaccine in pregnant and lactating animals has not been investigated.
However rabies virus and attenuated rabies vaccine viruses do not usually accumulate in reproductive organs and are not known to directly affect reproductive functions.
Immunocompromised/ immunosuppressed individuals must not be allowed to handle this vaccine.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet or the label to the physician.
The import, sale, supply and/ or use of this veterinary medicinal product is or may be prohibited in certain Member States on the whole or part of their territory pursuant to national animal health policy.
Any person intending to import, sell, supply and/ or use the veterinary medicinal product must consult the relevant Member State’ s Competent Authority on the current vaccination policies prior to the import, sale, supply and/ or use.
Restricted to duly designated competent administrative authorities.
20/ 22 13.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Dispose of waste material and any unplaced baits at the end of the day of distribution by boiling or incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
14.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
16/ 04/ 2008
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu
15.
OTHER INFORMATION
Not all pack sizes may be marketed.
For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.
België/ Belgique/ Belgien VIRBAC BELGIUM S. A.
Rue de la station 17 B-1300 WAVRE Tel:
32 (0) 10 47 06 35 Република България VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Č eská republika VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Danmark VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Deutschland VIRBAC Tierarzneimittel GmbH West Rögen 20 D-23843 Bad Oldesloe Tel:
49 (4531) 805 555 Eesti OÜ ZOOVETVARU Pärnasalu 31 ET -76505 Saue/ Harjumaa, ESTONIA Tel: + 372 6 709 006 E-mail: margus@zoovet. ee
Luxembourg/ Luxemburg VIRBAC BELGIUM S. A.
Rue de la station 17 B-1300 WAVRE Tel:
32 (0) 10 47 06 35 Magyarország VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Malta VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Nederland VIRBAC NEDERLAND BV Hermesweg 15 NL-3771 ND-Barneveld Tel:
31 (0) 342 427 100 Norge VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Österreich VIRBAC Österreich GmbH Hildebrandgasse 27 A-1180 Wien Tel:
43 (0) 1 21 834 260
21/ 22 Ελλάδα VIRBAC HELLAS A. E.
23 rd Klm National Road Athens-Lamia 145 65 Agios Stefanos Athens - GREECE Tel: +30 210 6219520 E-mail: info@virbac. gr
Polska VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00
España VIRBAC ESPAÑA S. A.
ES-8950 Esplugues de Llobregat (Barcelona).
Tél.: + 34 93 470 79 40
Portugal VIRBAC DE Portugal LABORATÓRIOS LDA P-2080 Almeirim Tel:
(351) 243 570 500
France VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 E-mail: dar@virbac. fr
România VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00
Ireland C & M Veterinary Distributors Limited IE-Limerick Tel:
353 61 314 933
Slovenija VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00
Ísland VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Italia VIRBAC SRL Via dei Gracchi 30 I-20146 Milano Tel:
39 02 48 53 541 Κύπρος PANCHRIS FEEDS VETERINARY LTD Industrial Area Aradippou, 6302 Larnaca, Cyprus Tel: +357 24813333 Fax: +357 24813377 E-Mail: markita@panchris. com
Slovenská republika VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Suomi/ Finland VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00 Sverige VIRBAC S. A.
1ère avenue 2065 m – L. I. D F-06516 Carros Tel:
33 (0) 4 92 08 73 00
Latvija OÜ ZOOVETVARU Pärnasalu 31 ET - 76505 Saue/ Harjumaa, ESTONIA Tel: + 372 6 709 006 E-mail: margus@zoovet. ee Lietuva OÜ ZOOVETVARU Pärnasalu 31 ET - 76505 Saue/ Harjumaa, ESTONIA Tel: + 372 6 709 006 E-mail: margus@zoovet. ee
United Kingdom VIRBAC Ltd UK-Suffolk IP30 9 UP Tel:
44 (0) 1359 243243
22/ 22